Bausch+Lomb Results Presentation Deck
Total Bausch+Lomb P&L¹ (Non-GAAP)³
Bausch + Lomb
Vision Care Revenue
Surgical Revenue
Ophthalmic Pharmaceuticals
Revenue
Total Revenue
Adj. Gross Profit²,3
Adj. Gross Margin ³
R&D
R&D percent of Revenues
Adj. SG&A³
Adj. SG&A percent of Revenues³
Adj. EBITA 3
Depreciation
Stock Based Compensation
Adj. EBITDA 3,4
Adj. EBITDA Margin ³
Adj. Net Income ³
Adj EPS 3,5
1Q22
$560M
$174M
$155M
$889M
$541M
60.9%
$77M
8.7%
$338M
38.0%
$126M
$30M
$16M
$170M
19.1%
$85M
$0.24
1Q21
$556M
$162M
$163M
$881M
$548M
62.2%
$67M
7.6%
$316M
35.9%
$165M
$30M
$14M
$198M
22.5%
$93M
$0.27
Reported Change
1%
7%
(5%)
1%
(1%)
(130 bps)
(15%)
(7%)
(24%)
0%
(14%)
(14%)
(9%)
1. Products with sales outside the United States impacted by F/X changes..
2. Excludes amortization and impairments of intangible assets
BAUSCH+LOMB 3. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.
4. Includes transactional FX and NCI.
5. On a proforma basis after giving effect to the IPO.
Constant
Currency³
4%
11%
(3%)
4%
1%
(18%)
(10%)
(22%)
3%
(14%)
17%
(15%)
Organic Change³
4%
13%
(3%)
5%
+5% organic revenue growth ¹,3
Investment in R&D ($10M) and
SG&A ($22M) to support future
growth expectations
1Q22 impacted by macro market
conditions (i.e. China lockdown,
FX and inflation)
8View entire presentation